AviadoBio and King's College London have announced an expanded license agreement providing AviadoBio exclusive rights to apply the vMiX RNAi gene silencing platform across all human therapeutic areas. Building on their 2020 agreement, which granted AviadoBio rights to apply the platform to its pipeline of gene therapies in neurological diseases, this expansion opens potential applications across cardiovascular disease, nephrology, oncology and a range of other indications beyond the Central Nervous System (CNS).

The vMiX platform is designed to enable targeted, durable gene silencing using AAV as a delivery vehicle. By harnessing the natural cellular mechanism of RNAi, vMiX has the potential for sustained reduction of disease-causing gene expression following a single administration. The platform has the potential to silence up to 3 genes simultaneously and enable ‘silencing and replacement’ via inclusion of a transgene sequence within the construct. Silencing activity is tightly controlled to regions of disease pathology using tissue- or cell-specific promoters. The expanded license enables broader application of the platform through strategic collaborations and partnerships.

Lisa Deschamps, CEO, AviadoBio, said, "vMiX is a versatile RNAi platform with potential applications that extend well beyond the neurodegenerative indications where we have demonstrated its initial therapeutic potential. Expanding our vMiX license positions us to maximise the value of vMiX as a platform technology while we maintain focus on advancing our core neuroscience pipeline. We see clear opportunities to partner with companies best positioned to advance vMiX-enabled programs across cardiovascular disease, nephrology, oncology and other indications beyond our therapeutic focus."

The expanded agreement follows recent positive preclinical data for AVB-406, AviadoBio’s lead vMiX-enabled program in Alzheimer’s disease and other tauopathies, presented in three oral sessions at the American Society of Gene and Cell Therapy (ASGCT) 2026 Annual Meeting in May. The data—which included dose-dependent MAPT knockdown of up to 80 percent in the brain—demonstrate the vMiX platform’s potential to enable one-time, durable gene silencing and support its broader application across a wide range of diseases.

AviadoBio has been working since 2020 to optimise the vMiX platform and developed an efficient discovery engine workflow to identify new candidates utilising in-silico, in-vitro and in-vivo design and selection. This enables rapid progression of development timelines and processes to dramatically decrease time to first-in-human trials.

Professor Sebastien Ourselin FREng FMedSci, Assistant Principal (Innovation), King’s College London, said, “The vMiX platform reflects the depth of translational research emerging from King’s College London and the strength of our long-standing partnership with King’s spinout, AviadoBio. We are delighted to expand our agreement with AviadoBio and extend vMiX platform’s application beyond neurological disorders across all human therapeutic areas. This expanded license reflects both the versatility of the technology and the value of sustained collaboration between academia and industry in accelerating the development of innovative therapies for patients with significant unmet medical needs.”